During a period of rapid fluctuation in the intravenous iron market, there was increased use of a more expensive drug that afforded providers additional revenue.
Bryan C. Hambley, MD, MPH
Advertisement
Articles by Bryan C. Hambley, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Patient Portal Messages Outpace Office Visits
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5